CN109789224A - 靶向il-6和cd126的dna单克隆抗体 - Google Patents

靶向il-6和cd126的dna单克隆抗体 Download PDF

Info

Publication number
CN109789224A
CN109789224A CN201780041454.5A CN201780041454A CN109789224A CN 109789224 A CN109789224 A CN 109789224A CN 201780041454 A CN201780041454 A CN 201780041454A CN 109789224 A CN109789224 A CN 109789224A
Authority
CN
China
Prior art keywords
ser
seq
val
leu
thr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201780041454.5A
Other languages
English (en)
Chinese (zh)
Inventor
大卫·韦纳
萨拉·埃利奥特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Pennsylvania
The Wistar Institute
Original Assignee
University of Pennsylvania
The Wistar Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Pennsylvania, The Wistar Institute filed Critical University of Pennsylvania
Publication of CN109789224A publication Critical patent/CN109789224A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0066—Manipulation of the nucleic acid to modify its expression pattern, e.g. enhance its duration of expression, achieved by the presence of particular introns in the delivered nucleic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0009—Galenical forms characterised by the drug release technique; Application systems commanded by energy involving or responsive to electricity, magnetism or acoustic waves; Galenical aspects of sonophoresis, iontophoresis, electroporation or electroosmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/248—IL-6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Virology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CN201780041454.5A 2016-05-05 2017-05-05 靶向il-6和cd126的dna单克隆抗体 Pending CN109789224A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662332377P 2016-05-05 2016-05-05
US62/332,377 2016-05-05
PCT/US2017/031193 WO2017192933A1 (en) 2016-05-05 2017-05-05 Dna monoclonal antibodies targeting il-6 and cd126

Publications (1)

Publication Number Publication Date
CN109789224A true CN109789224A (zh) 2019-05-21

Family

ID=60203626

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780041454.5A Pending CN109789224A (zh) 2016-05-05 2017-05-05 靶向il-6和cd126的dna单克隆抗体

Country Status (12)

Country Link
US (1) US20190192692A1 (cg-RX-API-DMAC10.html)
EP (1) EP3452106A4 (cg-RX-API-DMAC10.html)
JP (3) JP7311113B2 (cg-RX-API-DMAC10.html)
KR (3) KR20250011241A (cg-RX-API-DMAC10.html)
CN (1) CN109789224A (cg-RX-API-DMAC10.html)
AU (2) AU2017261292B2 (cg-RX-API-DMAC10.html)
BR (1) BR112018072697A2 (cg-RX-API-DMAC10.html)
CA (1) CA3023089A1 (cg-RX-API-DMAC10.html)
EA (1) EA201892524A1 (cg-RX-API-DMAC10.html)
MX (2) MX2018013523A (cg-RX-API-DMAC10.html)
SG (2) SG10202011023YA (cg-RX-API-DMAC10.html)
WO (1) WO2017192933A1 (cg-RX-API-DMAC10.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110167584A (zh) * 2016-11-07 2019-08-23 威斯塔解剖学和生物学研究所 用于针对莱姆病的dna抗体构建体

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102635888B1 (ko) 2019-03-19 2024-02-15 엘지전자 주식회사 공기청정기
EP4277929A1 (en) * 2021-01-14 2023-11-22 Translate Bio, Inc. Methods and compositions for delivering mrna coded antibodies

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070154481A1 (en) * 2005-12-09 2007-07-05 Gelinas Richard E Antibody Molecules Having Specificity For Human IL-6
CN104853782A (zh) * 2012-12-13 2015-08-19 宾夕法尼亚大学理事会 Dna抗体构建体及其使用方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0214168B8 (pt) * 2001-11-14 2021-05-25 Centocor Inc anticorpos anti-il-6, moléculas de ácido nucleico codificando os mesmos, vetores compreendendo as referidas moléculas, composições e formulações compreendendo os referidos anticorpos, bem como métodos de produção dos mesmos
PA8672101A1 (es) * 2005-04-29 2006-12-07 Centocor Inc Anticuerpos anti-il-6, composiciones, métodos y usos
WO2008019061A2 (en) * 2006-08-03 2008-02-14 Vaccinex, Inc. Anti-il-6 monoclonal antibodies and uses thereof
JP2011520898A (ja) * 2008-05-13 2011-07-21 ノビミューン エスアー 抗il−6/il−6r抗体およびそれらの使用方法
WO2011084714A2 (en) * 2009-12-17 2011-07-14 Biogen Idec Ma Inc. STABILIZED ANTI-TNF-ALPHA scFv MOLECULES OR ANTI-TWEAK scFv MOLECULES AND USES THEREOF
US8992908B2 (en) * 2010-11-23 2015-03-31 Alderbio Holdings Llc Anti-IL-6 antibodies for the treatment of oral mucositis
IL312865B2 (en) * 2013-09-11 2025-06-01 Eagle Biologics Inc Liquid protein formulations containing viscosity-lowering agents
WO2015054293A1 (en) * 2013-10-07 2015-04-16 Alder Biopharmaceuticals, Inc. Anti-il-6 antibodies for the treatment of psoriatic arthritis

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070154481A1 (en) * 2005-12-09 2007-07-05 Gelinas Richard E Antibody Molecules Having Specificity For Human IL-6
CN104853782A (zh) * 2012-12-13 2015-08-19 宾夕法尼亚大学理事会 Dna抗体构建体及其使用方法
US20150284448A1 (en) * 2012-12-13 2015-10-08 Inovio Pharmaceuticals, Inc. Dna antibody constructs and method of using same

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
SARAH T. C. ELLIOTT等: "In Vivo Expression of Functional DNA Monoclonal Antibodies Targeting IL-6 and CD126", 《MOLECULAR THERAPY》 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110167584A (zh) * 2016-11-07 2019-08-23 威斯塔解剖学和生物学研究所 用于针对莱姆病的dna抗体构建体
CN110167584B (zh) * 2016-11-07 2024-06-07 威斯塔解剖学和生物学研究所 用于针对莱姆病的dna抗体构建体

Also Published As

Publication number Publication date
AU2017261292A1 (en) 2018-12-20
JP2019518074A (ja) 2019-06-27
JP2023086734A (ja) 2023-06-22
KR20190031439A (ko) 2019-03-26
JP7311113B2 (ja) 2023-07-19
BR112018072697A2 (pt) 2019-02-19
WO2017192933A1 (en) 2017-11-09
KR20250011241A (ko) 2025-01-21
EP3452106A4 (en) 2020-01-08
JP2025147175A (ja) 2025-10-06
AU2024203109A1 (en) 2024-05-30
AU2017261292B2 (en) 2024-06-06
US20190192692A1 (en) 2019-06-27
AU2024203109B2 (en) 2026-05-21
EP3452106A1 (en) 2019-03-13
MX2025009846A (es) 2025-09-02
KR20230058733A (ko) 2023-05-03
SG10202011023YA (en) 2020-12-30
EA201892524A1 (ru) 2019-04-30
SG11201809786TA (en) 2018-12-28
CA3023089A1 (en) 2017-11-09
MX2018013523A (es) 2019-06-10

Similar Documents

Publication Publication Date Title
AU2017261374B2 (en) DNA antibody constructs for use against pseudomonas aeruginosa
JP2023086734A (ja) Il-6及びcd126を標的とするdnaモノクローナル抗体
CN110325546B (zh) 靶向流感病毒的dna单克隆抗体
KR20220117915A (ko) 항-muc1 조성물 및 사용 방법
US20240376179A1 (en) Dna antibody constructs for use against middle east respiratory syndrome coronavirus
BR112019020235A2 (pt) molécula de ácido nucleico, composição, e, métodos para tratar uma doença num indivíduo e para induzir uma resposta imunológica num indivíduo.
JP2023126321A (ja) ライム病に対する使用のためのdna抗体構築物
HK40009046A (en) Dna monoclonal antibodies targeting il-6 and cd126
US20230340082A1 (en) Dna antibody constructs for use against rotavirus
RU2813829C2 (ru) Конструкции днк-антител для применения против болезни лайма
EA042308B1 (ru) Днк-моноклональные антитела, нацеленные на il-6
HK40013455A (zh) 用於针对莱姆病的dna抗体构建体
WO2019152602A1 (en) Structurally modified flavivirus dmabs
WO2019152607A1 (en) Nucleic acid antibody constructs for use against ebola virus
KR20190114963A (ko) 에볼라 바이러스에 대한 사용을 위한 dna 항체 작제물
HK40014682B (en) Combination of novel vaccines against zika virus and dna antibody constructs for use against zika virus
HK40009739A (en) Dna antibody constructs and method of using same

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40009046

Country of ref document: HK